Highest-materiality recent filing
60 Degrees Pharmaceuticals appoints Eric Francois to Board of Directors
Eric Francois appointed to board effective May 13, 2026; compensation consistent with standard non-employee director arrangements.
60 Degrees Pharmaceuticals corrects beneficial ownership disclosure in March 13 prospectus
March 13 prospectus supplement incorrectly reported affiliate's beneficial ownership as 21,490 shares; correct is 23,367.
60 Degrees Pharmaceuticals files updated legal opinion for ATM program
Filed updated legal opinion of Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.
60 Degrees Pharmaceuticals files updated legal opinion for ATM program
Filed updated legal opinion from Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.
Received Nasdaq notice on Feb 11 confirming compliance with minimum bid price rule 5550(a)(2).
Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation
Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.
60 Degrees Pharmaceuticals to effect 1:4 reverse stock split effective Jan 20, 2026
Reverse split at 1:4 ratio effective Jan 20, 2026 at 12:01 AM ET before market open.
Company made investor presentation available on January 8, 2026, in connection with RedChip webinar.
60 Degrees Pharma shareholders approve reverse split, equity plan amendment at annual meeting
Five directors elected: Geoffrey Dow, Charles Allen, Cheryl Xu, Stephen Toovey, Paul Field.
60 Degrees Pharmaceuticals presents at H.C. Wainwright; no specific updates disclosed in filing
CEO Geoff Dow scheduled to present to investors starting September 9, 2025.
60 Degrees Pharmaceuticals enters $1.4M ATM offering with H.C. Wainwright, terminates prior ATM
Entered ATM Sales Agreement with H.C. Wainwright to sell up to $1,397,533 of common stock.
60 Deg Pharma closes $5M public offering, up to $10M with warrant exercise
Gross proceeds $5M from sale of 2,631,578 units (share/pre-funded warrant + warrants) at $1.90/unit.
On May 13, 2026, the Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc. (the “Company”) appointed Eric Francois to serve as a member of the Board, effective immediately.
Max materiality 0.85 · Median 0.40 · Most common event other_material